Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy? The Motley Fool
Covered in this story
What has happened since
- Lilly (Eli) is up 0.0% since this was published, 2 days ago.
- Novo Nordisk is up 1.6% since this was published, 2 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Lilly (Eli)
- Freedom Broker: at $1.42k · target $1.6k by Oct 2027 · Buy via Investing.com
- Bernstein: at $1.42k · target $1.45k by Oct 2027 · Outperform via Investing.com
- BMO Capital Markets: at $1.42k · target $1.65k by Oct 2027 · Outperform via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $LLY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Lilly (Eli) →Dalsna Finance is currently tracking 6 stories mentioning Lilly (Eli), the earliest published 9 Sept 2026.
Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.